Arxada is a global leader in innovative solutions that protect our world. Our groundbreaking technologies, in-depth regulatory know-how, manufacturing and process development help our customers to safeguard nutrition, health and infrastructure efficiently through chemistry and microbiology that enhance sustainability. We offer a broad portfolio of ingredients and services for multiple end-markets that include Human Health & Nutrition, Home & Personal Care, Professional Hygiene, Paints & Coatings and Wood Protection. With customers in more than 100 countries, the company achieved sales of CHF 2billion in 2025. Headquartered in Basel (Switzerland), Arxada employs 3,100 associates across 24 production sites and 14 R&D centers, all committed to our customers’ success.

To learn more about Arxada, please visit: arxada.com and Arxada on LinkedIn.

This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities referred to in this announcement, in any jurisdiction, including the United States, in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or an exemption from registration.

To the extent that any securities are issued pursuant to the Scheme, such securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or with any securities regulatory authority or under any relevant securities laws of any state or other jurisdiction of the United States. Any securities delivered under the Scheme may not be offered, sold, pledged or otherwise transferred except to (1) with respect to U.S. holders, to: (x) "qualified institutional buyers" within the meaning of Rule 144A under the U.S. Securities Act, or (y) institutional accredited investors (as defined in Rule 501(a)(1), (2), (3) or (7), (8), (9), (12) or (13) of Regulation D under the U.S. Securities Act), in each case, transacting in a private transaction in reliance upon an exemption from the registration requirements of the U.S. Securities Act; or (2) outside the United States to: (x) a holder who is not a "U.S. person" (as such term is defined in Rule 902 under the U.S. Securities Act) that is outside the United States transacting in offshore transactions in reliance on Regulation S under the U.S. Securities Act; and (y) if located in the European Economic Area, are persons who are not retail investors, being a person who is not one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU; or (ii) a customer within the meaning of Directive 2016/97/EU, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of Directive 2014/65/EU; or (iii) a "qualified investor" as defined in Regulation (EU) 2017/1129; or if located in the United Kingdom, are persons who are not retail investors in the United Kingdom, being a person who is not either one (or both) of the following: (i) a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No. 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; or (ii) a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024. No public offering of such securities will be made in the United States.

This announcement is for information purposes only, and no recommendation is being made as to whether the Creditors should consent to the Scheme. The Explanatory Statement contains important information which should be read carefully before any decision is made with respect to the Scheme. The Explanatory Statement should be consulted for additional information regarding consent procedures and the conditions for the Scheme. If any Creditor is in any doubt as to the action it should take or is unsure of the impact of the implementation of the Scheme, it is recommended to seek its own financial, accounting and legal advice, including as to any tax consequences, immediately from its stockbroker, bank, manager, solicitor, accountant or other independent financial, legal or tax adviser.

This announcement contains forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated timing of future announcements and the implementation the A&E Transaction. Forward-looking statements are based on our current expectations and assumptions and are subject to risks and uncertainties, many of which are outside our control, that could cause actual results or outcomes to differ materially from those expressed or implied in those statements. No assurance can be given that the matters described in these forward-looking statements will occur as described or at all. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.